See also this year's filing and all EDGAR filings for this company.
PDF Report 0001386570_2012_Niagen_Bioscience_Inc.pdf
Logs
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Assets', 'missing_ratio': 0.018571011428415, 'aggregate_val': 9034521, 'exp_sum': 9205476, 'exp_to_value': {'AssetsCurrent': 7927140, 'AssetsNoncurrent': 170955, 'PropertyPlantAndEquipmentNet': 936426, 'Goodwill': 136182, 'remainder_Assets': 34773}} |
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Assets', 'missing_ratio': 0.02249160842322545, 'aggregate_val': 6269905, 'exp_sum': 6414170, 'exp_to_value': {'AssetsCurrent': 4953352, 'AssetsNoncurrent': 144265, 'PropertyPlantAndEquipmentNet': 1172288, 'Goodwill': 100106, 'remainder_Assets': 44159}} |
Graph
Absolute values for 0001386570, Niagen Bioscience Inc
| xvar | xval | |
|---|---|---|
| 0 | LiabilitiesNoncurrent | 0 |
| 1 | LiabilitiesCurrent | 3,343,000 |
| 2 | remainder_Liabilities | 0 |
| 3 | AssetsCurrent | 4,953,352 |
| 4 | AssetsNoncurrent | 144,265 |
| 5 | PropertyPlantAndEquipmentNet | 1,172,288 |
| 6 | Goodwill | 100,106 |
| 7 | remainder_Assets | -100,106 |
| 8 | GeneralAndAdministrativeExpense | 15,976,849 |
| 9 | ResearchAndDevelopmentExpense | 0 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 8,112,610 |
| 12 | remainder_NetIncome | -30,745 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Liabilities | 3,343,000 |
| 1 | Assets | 6,269,905 |
| 2 | Expenses | 15,976,849 |
| 3 | Revenues | 8,112,610 |
| 4 | StockholdersEquity | 2,926,905 |
| 5 | NetIncome | -7,894,984 |
| 6 | ComprehensiveNetIncome | -7,894,984 |
| 7 | BaseVar | 16,866,554 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | -0.808 |
| 9 | EconomicCapitalRatio | 0.732 |
Edgar->Model Mapping
Feature Distribution
